Amarin Corporation Plc

Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale. The company was founded by Geoffrey W. Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amarin reports robust Q4 earnings, eyes global expansion opportunities

Amarin's Q4 2022 earnings call highlighted strong financial performance, successful global expansion efforts, and a focus on cash preservation and talent acquisition. The company's UK launch milestones and international progress position it well for future growth.

Amarin reports Q1 revenue growth amidst pricing challenges and opportunities

Amarin focuses on revenue growth and cost-saving initiatives to drive operational efficiency and profitability.
The company's strong cash position provides stability for future growth initiatives and strategic investments.
Challenges include pricing pressure from generics and the need to balance expenses with revenue growth.
Opportunities lie in expanding prescription growth, product portfolio, and exploring strategic partnerships.

Amarin Corporation Plc reports robust Q3 earnings and strategic growth plans

Amarin Corporation Plc's Q3 2023 earnings call showcased strong financial performance, operational decisions driving positive cash flow, and a focus on maximizing shareholder value. While challenges in the European market and uncertainties around stock price were noted, opportunities for growth in global markets and strategic initiatives offer potential for future success.

Amarin reports solid Q4 revenue growth and eyes global expansion

Amarin's Q4 2023 performance reflects revenue growth and ongoing investment in strategic initiatives.
The company's strong financial position and operational momentum in key markets position it well for future growth.
Challenges around market dynamics, expenses management, and competition require strategic focus for sustained success.

Amarin reports stable Q1 earnings, focuses on European growth opportunities

Amarin Corporation's Q1 2024 earnings call highlighted solid financial performance, successful IP defense in Europe, and positive clinical outcomes for its key products. While facing challenges in the U.S. market due to generic competition, the company maintains profitability and a strong cash position. Opportunities lie in shareholder value enhancement and continued growth in Europe.

Amarin reports stable revenue but faces generic competition challenges

Amarin's Q2 2024 performance reflects revenue decline in the U.S. due to generic competition but improved net income from expense reductions. The company's strengths lie in the success of Vascepa/VAZKEPA and maintaining market share. Challenges include adapting to changing market dynamics, while opportunities exist in global expansion and strategic initiatives.

Amarin reports Q3 revenue of $42.3M, focuses on global expansion

Amarin's Q3 2024 performance reflects a mixed financial outcome with total net revenue of $42.3M and a GAAP net loss of $25.1M, impacted by challenges in the U.S. generic market.
Despite facing pricing pressures and cost reduction efforts, the company maintains a stable cash position of $306M and remains focused on global expansion.
The strengths lie in the proven science and support for VASCEPA/VAZKEPA, with opportunities to address the unmet need in reducing cardiovascular disease globally.
Challenges include navigating market dynamics and maintaining profitability amidst pricing pressures, while upcoming events signal proactive engagement for long-term value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Amarin Corporation plc (AMRN) CEO John Thero Presents at Cantor Virtual Global Healthcare Conference (Transcript)

DUBLIN, Ireland and BRIDGEWATER, N.J., Sept.  09, 2020  (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) announced today that John F. Thero, Amarin's president and chief executive officer, is scheduled to present at the 2020 Cantor Virtual Global Healthcare Conference on Wednesday, September 16, 2020 from 11:20 - 11:50 a.m. Eastern Time.

Amarin to Present at the 2020 Cantor Virtual Global Healthcare Conference

Amarin shares have taken a beating this week during the appellate hearing and especially after the adverse ruling came down on September 3.

Amarin Is A Good Contrarian Pick To Consider After Post-Appeal Sell-Off

Amarin (AMRN) receives a setback as the U.S. Court of Appeals upholds a ruling by Nevada district court in favor of the generic companies related to patent litigation against Vascepa.

Amarin Loses Patent Appeal in Vascepa Lawsuit, Stock Dips

Just one day after hearing arguments, the U.S. Court of Appeals delivered a ruling that Amarin shareholders did not want to hear.

Appeals Court Rules Against Amarin in Vascepa Patent Dispute

DUBLIN, Ireland and BRIDGEWATER, N.J., Sept.  03, 2020  (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today provided an update following the decision by the U.S. Court of Appeals for the Federal Circuit in the company’s ongoing patent litigation. The Court upheld the March ruling by the U.S. District Court for the District of Nevada in favor of two generic companies in connection with their abbreviated new drug applications, or ANDAs, related to Amarin’s VASCEPA® (icosapent ethyl) capsule franchise. Amarin is currently reviewing its legal options and within 30 days expects to file a petition for an en banc review of the current panel decision by the full panel of 12 active judges at the U.S. Court of Appeals for the Federal Circuit.  

Amarin Provides Update Following Ruling in VASCEPA® ANDA Patent Litigation

Amarin's Vascepa Data, And Other News: The Good, Bad And Ugly Of Biopharma

Los Angeles, California--(Newsfile Corp. - September 2, 2020) -  The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Amarin Corporation plc ("Amarin" or "the Company") (NASDAQ: AMRN) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Amarin Corporation plc and Encourages Investors with Losses of $100,000 to Contact the Firm

Peloton

SmileDirectClub

DocuSign

MongoDB

Peloton, Docusign, MongoDB, Amarin and SmileDirectClub were our top stock trades for Thursday. So, let's take a closer look at the charts.

5 Top Stock Trades for Thursday: PTON, DOCU, MDB, SDC, AMRN

An appeal hearing for Vascepa's patent case isn't sitting well with investors.

Why Amarin Stock Is Getting Slammed Today

Amarin Corporation plc (NASDAQ: AMRN) shares were plummeting on above-average volume as an appeal hearing on the Vascepa fish oil capsule patent gets underway.

Why Amarin Shares Are Plunging Wednesday

Amarin Corporation: Bullish Financials Point To A Higher Share Price

VASCEPA is the first and only agent studied on top of statin therapy reported to exhibit coronary plaque regression in hypertriglyceridemic patients

Amarin Supports Latest Clinical Research Evaluating VASCEPA® (Icosapent Ethyl) in Patients with Persistent Cardiovascular Risk Presented at ESC Congress 2020, the Annual Meeting of the European Society of Cardiology

Primary endpoint of slowed coronary plaque progression reported to have been met with VASCEPA

VASCEPA® (Icosapent Ethyl) Reported to Significantly Reduce Coronary Plaque in EVAPORATE Study Final Results Presented at ESC Congress 2020

Amarin (AMRN) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Amarin (AMRN) in Focus: Stock Moves 5.5% Higher

Amarin Corp (NASDAQ: AMRN) shares are trading higher on Wednesday after Piper Sandler initiated coverage on the company's stock with an Overweight rating and announced a $21 price target.

Why Amarin's Stock Is Trading Higher Today

Amarin-Supported Research and Analyses from Academic Collaborators to Be Featured in Five Presentations, Including Late-Breaking Science Presentation of Final EVAPORATE Study Results Amarin-Supported Research and Analyses from Academic Collaborators to Be Featured in Five Presentations, Including Late-Breaking Science Presentation of Final EVAPORATE Study Results

Latest Clinical Research Evaluating VASCEPA® (Icosapent Ethyl) in Patients with Residual Cardiovascular Risk to be Presented at ESC Congress 2020, the Annual Meeting of the European Society of Cardiology

Amarin Corp.: Whether Vascepa Is A COVID-19 Play

Amarin's (AMRN) revenue growth in the second quarter is attributable to continued demand for its cardiovascular drug, Vascepa.

Amarin (AMRN) Beats on Q2 Earnings, Focuses on Europe

The company's second-quarter earnings report was less than encouraging.

4 Reasons Amarin Stock Could Tumble Even Further

Amarin Corporation plc's (AMRN) CEO John Thero on Q2 2020 Results - Earnings Call Transcript

Amarin Corporation plc (NASDAQ: AMRN) shares were advancing strongly Tuesday following the release Tuesday of second-quarter results.

Amarin Reports Mixed Q2 As COVID-19 Weighs On Results; Analyst Sees Favorable Risk-Reward

The big wild card for the company now is its appeal of a court ruling invalidating key patents for the high triglyceride drug.

Amarin's Vascepa Sales Jump 34% in Q2 Despite COVID-19 Headwinds

Amarin Corp. PLC (NASDAQ: AMRN) reported its latest quarterly results on Tuesday morning and gave an update on the most recent developments with its blockbuster drug Vascepa.

Is European Update Overshadowing Amarin’s Lackluster Earnings?

Amarin to Build Dedicated Organization to Retain Substantial Value of One of the Most Anticipated Cardiovascular Drug Products in Decades

News for Amarin Corporation Plc Stock (AMRN)